Quest Laboratories

What Quest Laboratories does

Quest Laboratories Limited is a publicly listed Indian pharmaceutical manufacturer headquartered in Pithampur, Dhar district, Madhya Pradesh, producing a portfolio of 1,300 molecules across tablets (uncoated, film coated, enteric coated, and sustained release), liquid orals, dry syrups, suspensions, powders (including WHO-formula ORS), ointments, creams, and external liquids. The company holds WHO GMP, CGMP, GLP, GSP, and ISO 9001:2000 certifications issued by FDA Bhopal, with more than 900 FDA-approved formulations. Manufacturing capacity stands at 10 crore tablets, 2 lakh bottles of oral syrup, 50,000 tubes, and 2.50 lakh ORS pouches per day, currently operating at 90% installed capacity following an October 2023 capacity expansion. The company also operates an in-house quality control laboratory with HPLC, GC, FTIR, UV, and dissolution testing equipment, and an in-house R&D function supporting complex formulation capabilities such as sustained release, fast-dissolving, and bitter-masking drugs. The company is currently planning entry into injectable vials, ampoules, dry injections, and dedicated anti-cancer drugs.

The company serves four primary customer segments: state government medical corporations (Uttar Pradesh, Madhya Pradesh, Jammu & Kashmir, Bihar, and Jharkhand) through tender-based live rate contracts; other pharmaceutical companies through contract manufacturing; PCD (Propaganda-cum-Distribution) franchise partners distributing to the domestic retail market; and the broader Indian retail pharmacy market across chronic and acute therapy categories including antibiotics, anti-malarials, anti-spasmodics, anti-inflammatory, anti-emetic, respiratory, diabetes, and anti-depression medications. Q3 FY2026 (December 2025 quarter) standalone revenue was Rs 30.61 crore, up 106.27% year-over-year, with net profit of Rs 4.03 crore (up 416.67% YoY) and operating margin expanding to 22.57% from 4.51% in the prior year period. The company is publicly listed on NSE (nse:QUESTLAB) and is founder-controlled, with Anil Kumar Sabarwal as Chairman and Managing Director, Tejaswini Sabarwal as Whole Time Director, and Rahul Dangi as Whole Time Director overseeing production.

Name

Quest Laboratories

Legal name

Quest Laboratories Limited

Website

https://questlabltd.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

Quest Laboratories Limited is a publicly listed Indian pharmaceutical manufacturer producing generic formulations across tablets, syrups, ointments, ORS powders, and injectables at a WHO GMP-certified facility in Pithampur, Madhya Pradesh, supplying government medical corporations, PCD franchise distributors, and contract manufacturing clients in India and planned export markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing (Generic Formulations)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

Keywords

• Pharmaceutical manufacturing
• Generic formulations
• Contract manufacturing
• Institutional drug supply
• PCD franchise distribution

Headquarters

HQ city

Dhar

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and selling pharmaceutical formulations including tablets, syrups, ointments, powders, and injectables through domestic ethical market, institutional supplies, PCD franchise, and contract manufacturing arrangements
2. Contract Manufacturing: Manufacturing facility for contract production of specified formulations and molecules for other pharmaceutical companies
3. Institutional/Government Supplies: Supply of essential medicines to government medical corporations through tender contracts including UP Medical Corporation, MP Medical Corporation, Jammu Medical Corporation, Bihar and Jharkhand
4. Product Sales - Q3 FY2026: Rs 30.61 crore sales revenue for quarter ended December 2025 with 106.27% year-over-year surge

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Quest Laboratories Limited is a pharmaceutical manufacturer that produces generic and branded-generic drug formulations across tablets, liquid orals, dry syrups, powders, ointments, creams, suspensions and external liquids. Its commercial model is built on three pillars: institutional/government supply to state medical corporations through tenders, PCD franchise distribution for the domestic ethical market, and contract manufacturing of specified formulations and molecules for other pharmaceutical companies. The company also offers technology-intensive products such as sustain release, fast-dissolving, and bitter masking formulations, with planned entry into injectable vials, ampoules, dry injections, and oncology drugs.

Product overview

Quest Laboratories Ltd is a pharmaceutical manufacturer producing a diverse portfolio of generic drug formulations across multiple dosage forms. Their product portfolio includes Tablets (uncoated, film coated, enteric coated, and sustained release formulations) such as Chlorpheniramine Maleate Tablets, Metformin Hydrochloride Tablets, Metronidazole Tablets, Dicyclomine Hydrochloride Tablets, Paracetamol & Dicyclomine Hydrochloride Tablets, and Dexamethasone Tablets (Dexlysone); Dry Syrups including Cyproheptadine Hydrochloride & Tricholine Citrate Syrup, Levosalbutamol Sulphate/Ambroxol Hydrochloride & Guaiphenesin Syrup, and Cypronex-T Syrup; Suspension products such as Azithromycin Oral Suspension IP; Ointments including Povidone-Iodine Ointment U.S.P. and Dard-E-Hayat; and Powder formulations including ORAL REHYDRATION SALTS IP and DEXTROSE MONOHYDRATE POWDER IP. The company also produces Liquid Orals, External Liquids, and is expanding into Injectable Vials, Ampoules, and Dry Injections for oncology. They operate WHO GMP, GMP, and GLP certified manufacturing facilities with over 900 FDA-approved formulations covering various therapeutic segments including antibiotics, antimalarial, antispasmodic, anti-inflammatory, anti-emetic, respiratory, diabetes, and anti-depression medications.

Differentiator

Problem solved

Functional benefit

Products and services

• Chlorpheniramine Maleate Tablets IP 4 mg Antihistamine tablet used for the treatment of allergic conditions. Sold in the generic-pharmaceutical market through Quest's domestic ethical, PCD and institutional channels.
• Metformin Hydrochloride Tablets IP 500 mg Oral antidiabetic medication used for the management of type 2 diabetes. Sold in the generic-pharmaceutical market through Quest's domestic ethical, PCD and institutional channels.
• Metronidazole Tablets IP 200 mg Antibiotic tablet used to treat parasitic and bacterial infections. Sold in the generic-pharmaceutical market through Quest's domestic ethical, PCD and institutional channels.
• Dicyclomine Hydrochloride Tablets IP 10 mg Antispasmodic tablet used for the relief of irritable bowel syndrome and abdominal cramps. Sold in the generic-pharmaceutical market through Quest's domestic ethical, PCD and institutional channels.
• Paracetamol & Dicyclomine Hydrochloride Tablets Combination analgesic and antispasmodic tablet used for the management of pain and abdominal cramps. Sold in the generic-pharmaceutical market through Quest's domestic ethical, PCD and institutional channels.
• Dexamethasone Tablets IP 0.5 mg (Dexlysone) Corticosteroid tablet used for anti-inflammatory and immunosuppressant therapy. Sold in the branded-generic pharmaceutical market through Quest's domestic ethical, PCD and institutional channels.
• Azithromycin Oral Suspension IP Antibiotic oral suspension used in the treatment of respiratory and other bacterial infections, particularly in pediatric and geriatric patients. Sold in the generic-pharmaceutical market through Quest's domestic ethical, PCD and institutional channels.
• Cyproheptadine Hydrochloride & Tricholine Citrate Syrup Syrup formulation combining an antihistamine (cyproheptadine) with tricholine citrate, used as an appetite stimulant with choline supplementation. Sold in the generic-pharmaceutical market through Quest's domestic ethical, PCD and institutional channels.
• Levosalbutamol Sulphate, Ambroxol Hydrochloride & Guaiphenesin Syrup Respiratory syrup combining a bronchodilator (levosalbutamol), a mucolytic (ambroxol) and an expectorant (guaiphenesin) for the symptomatic relief of productive cough and bronchospasm. Sold in the generic-pharmaceutical market through Quest's domestic ethical, PCD and institutional channels.
• Cypronex-T Syrup Branded respiratory and antihistamine syrup formulation sold in the domestic ethical, PCD and institutional channels.
• Povidone-Iodine Ointment U.S.P. Topical antiseptic ointment used for wound care and prevention of skin and wound infections. Sold in the generic-pharmaceutical market through Quest's domestic ethical, PCD and institutional channels.
• Dard-E-Hayat Branded topical analgesic ointment for the relief of muscular and joint pain. Sold in the branded-generic pharmaceutical market through Quest's domestic ethical, PCD and institutional channels.
• Oral Rehydration Salts IP (WHO Formula) WHO-formula oral rehydration salt powder used for the treatment and prevention of dehydration, particularly in diarrhea. Sold in the generic-pharmaceutical market through Quest's domestic ethical, PCD and institutional channels.
• Dextrose Monohydrate Powder IP Dextrose monohydrate powder used as a glucose and carbohydrate supplement for energy replenishment and oral rehydration support. Sold in the generic-pharmaceutical market through Quest's domestic ethical, PCD and institutional channels.
• Contract Manufacturing Services Contract manufacturing of specified pharmaceutical formulations and molecules for other pharmaceutical companies, leveraging Quest's WHO GMP / CGMP / GLP / ISO 9001:2000 certified facility, 900+ FDA-approved formulations, in-house QC laboratory and high-volume production capacity (10 crore tablets/day).
• Institutional / Government Pharmaceutical Supply Bulk supply of essential generic medicines to Indian state medical corporations and government hospitals on a tender / live-rate contract basis, including Uttar Pradesh Medical Corporation, Madhya Pradesh Medical Corporation, Jammu Medical Corporation, and recently added Bihar and Jharkhand Medical Corporations.

Quantifiable outcome

• 416.67% increase in net profit year-over-year
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Narendra PamechaminorOthersCo-founder and director at company formation in 1998; left the company in April 1999
• Kavita SabarwalcoreOthersM.Sc degree holder who joined as Director in February 1999 replacing Narendra Pamecha; contributed to merging ABC Pharmaceuticals and ABC Herbal Formulations into Quest

Scale indicators8 records

Recent moves13 records

Expansion highlights4 records

Direct peers

• Ajanta Pharma: Indian generic pharmaceutical manufacturer producing formulations across multiple therapeutic areas and dosage forms, with both domestic institutional/retail and export presence, directly comparable to Quest Labs' branded-generics and institutional supply model.
• Ipca Laboratories: Indian generic formulations manufacturer with WHO GMP facilities, an institutional and domestic branded generics franchise, and emerging market exports, very similar in product mix and channel structure to Quest Labs.
• Torrent Pharmaceuticals: Large Indian generic formulations company with strong presence in chronic and acute therapies, contract manufacturing, and emerging market exports; comparable product portfolio and WHO GMP manufacturing base.
• Lupin: Major Indian generic formulations manufacturer with a broad chronic and acute therapy portfolio, government/institutional supply, and global exports, comparable in business model and product breadth to Quest Labs.
• Glenmark Pharmaceuticals: Indian-headquartered global generic and specialty pharma player with a similar focus on formulations across respiratory, diabetes, antibiotics, and anti-inflammatory segments, with government/institutional supply and export channels.
• Mangalam Drugs & Organics: Small-cap Indian manufacturer of APIs and finished dosage forms selling into institutional and domestic channels, structurally similar to Quest Labs in scale, government-tender exposure, and product mix.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quest Laboratories